<DOC>
	<DOCNO>NCT00665561</DOCNO>
	<brief_summary>The study ass use maraviroc along optimize background regimen antiretroviral drug usual clinical practice safe use optimized regimen antiretroviral drug .</brief_summary>
	<brief_title>Prospective Observational Epidemiologic Study Maraviroc 's Safety</brief_title>
	<detailed_description>All patient meet study eligibility criterion participate site invited participate .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Treatment experience , HIV1 infect patient 18 year older Receive approve assay determination HIV1 tropism Pregnant lactate Using CCR5 inhibitor maraviroc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Maraviroc</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Safety</keyword>
	<keyword>Non-interventional</keyword>
</DOC>